recorded webinar

Management of Treatment Resistant Depression



Charles Nemeroff, MD, PhD
Wednesday, October 18, 2017 12:00 pm
- 1:00 pm ET

This presentation focuses on the factors associated with treatment-resistance including a history of child abuse and neglect, prominent anxiety and certain comorbid medical and psychiatric conditions.

It is now well-established that a minority of patients with major depression attain remission after treatment with antidepressant mono-therapy.

The importance of accurate diagnosis is highlighted including family history and evaluation for medical disorders associated with poor treatment response such as hypothyroidism and hypogonadism. Once a patient has failed an adequate trial of an antidepressant, a decision to either:                                             

1) increase the dose of the current antidepressant,
2) engage in combination therapy of the current agent and another antidepressant or evidence-based psychotherapy (e.g. CBT),
3) utilize an augmentation strategy by adding an agent (e.g. lithium or T3) that is not an effective antidepressant, but when added to an antidepressant converts non-remitters to remitters
4) switch to an entirely different antidepressant class, e.g. SSRI→SNRI or SSRI→MAOI 5) use a somatic non-pharmacological approach such as rTMS, VNS, or ECT.

The evidence for these approaches will be summarized.
Finally, the status of experimental treatments including ketamine and DBS is discussed.

At the end of this session, participants will be able to:

1. Understand factors associated with treatment resistant depression and the importance of accurate diagnosis for medical disorders associated with poor treatment response
2. Consider and weigh different options for deciding on how to address depression after the patient’s failure of an adequate trial of an antidepressant
3. Touch upon the status of experimental treatments such as ketamine and DBS

Presentation Level: Intermediate to Advanced: Assumes knowledge of basic treatment of depression with antidepressants and psychotherapy.

This webinar is not eligible for CE credit. 

Presenter(s) Biography

Charles Nemeroff, MD, PhD


Charles B. Nemeroff is currently the Professor and Chair, Department of Psychiatry and Director, Institute for Early Life Adversity Research. Previously, Dr. Nemeroff was the Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences, and Clinical Director of the Center on Aging at the University of Miami Miller School of Medicine.  He is past president of the American College of Psychiatrists and the American College of Neuropsychopharmacology.  His research has focused on the neurobiology of mood and anxiety disorders with a focus on the long term consequences of child abuse and neglect and how these changes increase vulnerability for psychiatric disorders in adulthood.  He has published more than 1000 research reports and reviews, and 15 books.  He is a member of the Institute of Medicine of the National Academy of Sciences (USA). Dr. Nemeroff is ADAA's Board President. 

Professional Post

ADAA Continuing Education Credits for Live and On-Demand Programming

Learners complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Some ADAA professional webinars focused on diversity or cultural competency subject matter are eligible for the Cross-Culture Competency Diversity Credit. If a webinar is eligible for this credit, it will be reflected on your credit certificate.

All continuing education credits are provided through Amedco, LLC. Learn more about the CE/CME accreditation information here.